A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow
| Autor: | Andreas D. Hartkopf, Sara Y. Brucker, Vincent P. Walter, Florin-Andrei Taran, Markus Wallwiener, Christina B. Walter, Diethelm Wallwiener, Eva-Maria Grischke |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Adult Cancer Research medicine.medical_specialty Neoplasm Residual Breast Neoplasms 03 medical and health sciences Cytokeratin 0302 clinical medicine Breast cancer MammaPrint Bone Marrow Internal medicine medicine Humans Aged biology medicine.diagnostic_test business.industry Gene signature Middle Aged medicine.disease Neoplastic Cells Circulating Prognosis Minimal residual disease 030104 developmental biology medicine.anatomical_structure Chemotherapy Adjuvant 030220 oncology & carcinogenesis Cohort biology.protein Keratins Female Bone marrow Antibody Neoplasm Recurrence Local business Transcriptome |
| Zdroj: | Breast cancer research and treatment. 169(2) |
| ISSN: | 1573-7217 |
| Popis: | The 70-gene signature (70-GS) is a prognostic tool, grouping patients in risk groups to assess their need for adjuvant chemotherapy. Tumor cell dissemination to the bone marrow is a marker of minimal residual disease and associated with impaired survival. In this study, we aimed to evaluate whether 70-GS is associated with the presence of disseminated tumor cells (DTCs) in the bone marrow of patients with early breast cancer. In patients with hormone receptor-positive HER2-negative early breast cancer, the 70-GS was obtained and the presence of DTCs was immunohistochemically evaluated using cytokeratin staining with the A45-B/B3 antibody. 149 patients were included into the analysis. 40 (27%) had a high-risk 70-GS and 35 (23%) had detectable DTCs in their bone marrow. 9 (22%) of the 40 patients with high-risk 70-GS and 26 (24%) of the 109 patients with a low-risk 70-GS were positive for DTCs (p = 0.863). As both 70-GS and DTC detection are known prognostic factors but do not seem to correlate, a follow-up on a larger cohort is warranted to evaluate if a combination of the two is able to better stratify the relapse risk in early breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink